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Original article
Proportions of B-cell subsets are altered in
incomplete systemic lupus erythematosus and
correlate with interferon score and IgG levels
Svenja Henning 1, Wietske M. Lambers1, Berber Doornbos-van der Meer1,
Wayel H. Abdulahad, Frans G. M. Kroese1, Hendrika Bootsma1,
Johanna Westra1 and Karina de Leeuw1
Abstract
Objectives. Incomplete SLE (iSLE) patients display symptoms typical for SLE but have insufficient criteria to fulfil
the diagnosis. Biomarkers are needed to identify iSLE patients that will progress to SLE. IFN type I activation, B-
cell-activating factor (BAFF) and B-cell subset distortions play an important role in the pathogenesis of SLE. The
aim of this cross-sectional study was to investigate whether B-cell subsets are altered in iSLE patients, and
whether these alterations correlate with IFN scores and BAFF levels.
Methods. iSLE patients (n¼ 34), SLE patients (n¼41) with quiescent disease (SLEDAI 4) and healthy controls
(n¼22) were included. Proportions of B-cell subsets were measured with flow cytometry, IFN scores with RT-PCR
and BAFF levels with ELISA.
Results. Proportions of age-associated B-cells were elevated in iSLE patients compared with healthy controls and
correlated with IgG levels. In iSLE patients, IFN scores and BAFF levels were significantly increased compared with
healthy controls. Also, IFN scores correlated with proportions of switched memory B-cells, plasma cells and IgG
levels, and correlated negatively with complement levels in iSLE patients.
Conclusion. In this cross-sectional study, distortions in B-cell subsets were observed in iSLE patients and were
correlated with IFN scores and IgG levels. Since these factors play an important role in the pathogenesis of SLE,
iSLE patients with these distortions, high IFN scores, and high levels of IgG and BAFF may be at risk for progres-
sion to SLE.
Key words: incomplete systemic lupus erythematosus, B-cell subsets, switched memory B-cells, age-associ-
ated B-cells, interferon, BAFF
Introduction
SLE is a systemic, chronic autoimmune disease with a
heterogenic clinical picture comprising a wide range of
symptoms. Symptoms typically present in a relapsing–
remitting pattern [1]. Given the heterogeneous nature of
the disease, it is difficult to diagnose SLE. Currently,
diagnosis is based on a combination of clinical and
serological hallmarks, summarized in the SLICC criteria,
ACR criteria and the newly formulated ACR-EULAR cri-
teria [2–4]. Some patients with clinical symptoms and
autoantibodies suggestive of lupus do not classify as
having SLE. This state of disease is referred to as in-
complete SLE (iSLE) [5]. This comprises a very hetero-
geneous group of patients, of which 20–57% will
eventually develop SLE [6].
Rheumatology key messages
. Age-associated B-cells are elevated in incomplete SLE and correlate with IgG levels.
. IFN scores and B-cell-activating factor levels are elevated in incomplete SLE patients.
. In incomplete SLE, proportions of switched memory B-cells, plasma cells and autoantibodies correlate with IFN
scores.
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It is unclear which factors determine progression from
iSLE to SLE and therefore, which iSLE patients will de-
velop SLE. Ideally, in the future biomarkers will indicate
which patients may progress from iSLE to SLE and
thereby help us understand and intervene in the patho-
genesis of SLE. The pathogenesis of SLE is highly com-
plex, involving both the innate and adaptive immune
system [1]. IFN—mainly type I—seems to play a key role
in the pathogenesis of SLE [7, 8]. Type I IFN serves as
an immune system primer that can help initiate both in-
nate and adaptive immune processes [9, 10]. Currently,
gene expression of several IFN response genes com-
bined in an IFN score is used as a surrogate marker to
quantify the amount of IFN, as IFN measurement itself is
not easily applicable [11].
Type I IFN can affect B-cell activation and can pro-
long B-cell survival via B-cell-activating factor (BAFF),
which prevents apoptosis of B-cells [8, 12]. BAFF is ele-
vated in patients with SLE and also a target of belimu-
mab, a novel mAb that is indicated in SLE patients who
are autoantibody-positive and have active disease.
Belimumab induces elimination of B-cells by binding to
BAFF and thereby limits disease flares in SLE patients
[13]. B-cells are central to the pathogenesis of SLE by
production of autoreactive antibodies, most importantly
ANAs. B-cells can also stimulate production of IFN by
plasmacytoid dendritic cells, which results in a vicious
cycle of autoimmune activation [14]. Several abnormal-
ities in subsets of circulating B-cells have been
described in SLE. For example, SLE patients have
higher numbers of circulating plasma blasts and plasma
cells compared with healthy controls (HCs) [15].
Switched memory B-cells (IgM, IgD, CD27þ) also
have effector functions, among which is the production
of (auto)antibodies, and are related to disease activity in
SLE [15]. Additionally, age-associated B-cells (ABCs),
also known as atypical B-cells and characterized by
CD19þCD21lowCD11cþ phenotype, have been found to
be elevated in SLE [16–18]. Also, ABCs express the
transcription factor T-bet [16]. It has been shown that T-
bet/CD11þ cells can differentiate into plasma cells [19].
T-bet can be activated by triggering B-cell receptor, IFN
and Toll-like receptor 7 (TLR7), leading to an increased
(auto)antibody production [16, 20].
In short, distortion of B-cell subset proportions, and
increased IFN scores and BAFF levels are central to the
pathogenesis of SLE. We hypothesize that high IFN
scores and BAFF levels promote B-cell activation and
survival, leading to alterations in proportions of B-cell
subsets, and thereby determine progression from iSLE
to SLE. Understanding the role of B-cell subsets, IFN
and BAFF might help to unravel the pathogenesis of
SLE. To this end, we assessed the distribution of circu-
lating B-cell subsets, IFN scores and serum BAFF levels
in iSLE patients, SLE patients with quiescent disease
(SLEDAI 4) and HCs.
Methods
Study population
Participants were eligible for the iSLE group if they had
ANA titre of >1:80, disease duration of <5 years and at
least one ACR or SLICC criterion, but not meeting ACR
or SLICC criteria for SLE. Patients with iSLE who used
immunosuppressive drugs, except for NSAIDs and
HCQ, were excluded. As a positive control group, SLE
patients with quiescent disease, i.e. SLEDAI of 4, were
included to allow comparison with iSLE patients. SLE
patients had to meet the ACR and/or SLICC criteria and
had a maximum disease duration of 10 years. HCs were
included if they did not have any history of autoimmune
disease, no infection at time of inclusion and did not use
immunosuppressive drugs.
Every participant gave informed consent before the
start of the study. The study protocol was in line with the
guidelines of the 1975 Declaration of Helsinki and has
been approved by the medical ethics committee of the
University Medical Centre Groningen (METc2015/313).
General sample processing
Blood was drawn in lithium heparin tubes and peripheral
blood mononuclear cells were isolated by Ficoll-Paque
density gradient centrifugation. These isolated cells were
stored in liquid nitrogen until further processing. Serum
samples for autoantibody measurement were separated
from clotted blood by centrifugation and stored at 20C.
Additionally, blood was drawn into PaxGene tubes and
stored at 80C after 2 h storage at room temperature.
Analysis of B-cell subsets
Stored peripheral blood mononuclear cells were thawed
in RPMI containing 10% fetal calf serum. mAbs were
added to tubes containing 1mio cells according to the
manufacturer’s instructions. After 30 min incubation at
4C, samples were washed with cold PBS and
eBioscience Fix/Perm Buffer (ThermoFisher Scientific,
Waltham, MA, USA) was added. After 45 min of incuba-
tion at 4C, samples were washed again with PBS. After
addition of mouse serum, intracellular staining markers
and isotype controls were added. Subsequently, cells
were washed twice and resuspended in 350 ll PBS.
Flowcytometric measurements were performed on the
LSR II flow cytometer (BD Biosciences, San Jose, CA,
USA). Spectral overlap was corrected for with bead iso-
types. Analysis and gating were performed with Kaluza
Analysis Software 2.1 (see supplementary Fig. S1, avail-
able at Rheumatology online, for gating strategy).
Standard gates were optically set based on cell popula-
tions of samples of 10 HCs. These standard gates were
then applied to all samples. To correct for batch effects,
every sample was checked individually, and the gates
adapted in a standardized manner if necessary. Results
are expressed as proportion of total B-cells. Absolute
numbers of different B-cell subsets were calculated
based on the standard lymphocyte counts.
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Analysis of autoantibodies
Anti-dsDNA autoantibodies and other autoantibodies
were measured by fluorescence enzyme immunoassay
using the automated EliA assay (ThermoFisher Scientific,
Nieuwegein, The Netherlands).
IFN score measurement
IFN scores were measured by RT-PCR. An IFN score
based on the following genes was calculated: IFI44L, LY6E
and MX1. These genes are most commonly used in litera-
ture and are representative for IFN type I expression [11].
First, RNA was isolated from whole blood stored in
PaxGene tubes, with a kit from Qiagen (Cat No./ID:
762164). Second, RNA was converted to DNA and con-
secutively, expression of several IFN genes was measured
by validated TaqMan assays. Results were expressed in
relative expression (RE), calculated according to the for-
mula: RE ¼ 2(Ct Test geneCt GAPDH). In this formula, Ct rep-
resents the cycle threshold and glyceraldehyde 3-
phosphate dehydrogenase the reference housekeeping
gene. RE values were converted to logarithmic values and




Based on our preliminary findings, we split iSLE
patients in two subgroups for comparative analysis. This
was based on high IFN scores with the median as cut-
off. We compared proportions of B-cell subsets, BAFF
levels and serological disease markers.
BAFF
Levels of BAFF were measured by ELISA (Duoset, R&D
Systems, Minneapolis, MN, USA). High performance
ELISA buffer (Sanquin, Amsterdam, The Netherlands) was
used during serum incubation to prevent non-specific
reactions. BAFF levels were considered elevated if they
were higher than þ2 S.D. above the mean of the HC group
(248 pg/ml).
Statistical analysis
Non-parametric data are reported as median and interquar-
tile range. Kruskal–Wallis tests were used for non-paramet-
ric, continuous data at group level. In case of significance,
Mann–Whitney U test was used for pairwise comparisons.
Correlations between B-cell subsets, IFN scores and BAFF
were assessed using Spearman’s correlation.
All statistical tests were performed in IBM SPSS Statistics
for Windows, version 23.0 (IBM Corp., Armonk, NY, USA)
and data were plotted in GraphPad Prism for Windows ver-
sion 8.2.1 (GraphPad Software, Lo Jolla, CA, USA). Two-
sided P<0.05 were considered statistically significant.
Results
Demographics
A total number of 97 participants was included, of which
34 classified as having iSLE and 41 as having SLE. The
age- and gender-matched HC group consisted of 22
participants (Table 1). Between groups, age was similar,
and most participants were female and Caucasian.
B-cell subsets
The proportions of transitional and naı̈ve B-cells were
similar between all groups (Fig. 1A and B). Also, we did
not find significant differences between proportions of
memory B-cells or plasma blasts/plasma cells between
all groups (Fig. 1C and D). Proportions of switched
memory B-cells were slightly increased in iSLE patients
compared with HCs [45.3% (37.6–53.8) vs 35.9% (28.2–
48.9); P¼0.07] and significantly increased in SLE
patients compared with HCs [52.0% (40.1–63.6);
P<0.01] (Fig. 1E). Proportions of switched memory B-
cells were not significantly different between iSLE and
SLE patients. The proportion of non-switched memory
B-cells was highest in HCs [57.6% (43.9–66.7)] and low-
est in SLE patients [41.3% (30.5–55.5)] (Fig. 1F). There
were no significant differences in proportions of IgD-only
memory B-cells between all groups (Fig. 1G). Lastly, we
found an elevated proportion of ABCs in iSLE patients
compared with HCs [1.9% (1.1–2.7) vs 1.2% (0.8–1.5);
P<0.05] (Fig. 1H). Absolute B-cell counts are shown in
supplementary Table S1, available at Rheumatology
online.
IFN score
We found higher IFN scores in iSLE patients compared
with HCs [3.3 (0.5–10.1) vs 0.5 (0.8 to 1.2); P<0.01].
IFN scores were not significantly different between iSLE
and SLE patients (Fig. 2). Based on the distribution of
IFN scores, iSLE patients were divided into two distinct
subgroups: IFNhigh (n¼16) and IFNlow (n¼17). IFNhigh
iSLE patients had IFN scores above the median.
IFNhigh iSLE patients had a higher proportion of transi-
tional B-cells [10.4% (5.1–13.6) vs 3.7% (2.4–7.4);
P¼0.001], switched memory B-cells [51.3% (39.5–62.7)
vs 41.0% (32.4–50.6); P¼ 0.04] and a lower proportion
of non-switched memory B-cells [45.7% (34.3–55.9) vs
56.8% (46.7–64.2); P¼0.02] compared with IFNlow iSLE
patients. There was a trend for proportions of plasma
blasts/plasma cells to be elevated in IFNhigh iSLE
patients compared with IFNlow iSLE patients [1.1% (0.5–
2.7) vs 0.5% (0.2–1.0); P¼ 0.08]. Proportions of other B-
cell subsets were not significantly different between
IFNhigh and IFNlow iSLE patients.
BAFF levels tended to be higher in IFNhigh iSLE
patients compared with IFNlow iSLE patients [208 pg/ml
(117–335)] vs 149 pg/ml (100–188); P¼0.06]. In addition,
IgG levels were significantly elevated in IFNhigh iSLE
patients compared with IFNlow iSLE patients [15.6 g/l
(10.4–20.4) vs 11.3 g/l (9.4–12.8); P¼ 0.007], as well as
anti-SSA autoantibodies [141.5 U/ml (0.3–240.0) vs
0.0 U/ml (0.0–16.5); P¼ 0.01). Anti-Smith and anti-
dsDNA autoantibodies were not elevated in IFNhigh iSLE
patients.
Five iSLE patients (14.7%) had low C3 levels (cut-
off <0.9 g/l) and also showed higher IFN scores
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compared with iSLE patients with normal C3 levels
(P¼0.01). Low C4 levels were observed in two iSLE
patients (6.1%), of which one patient showed high IFN
scores.
BAFF levels
Median levels of BAFF were significantly higher in iSLE
patients compared with HCs [171 pg/ml (111–240) vs
117 pg/ml (74–154); P<0.01], but similar to SLE patients
[184 pg/ml (124–254)]. BAFF levels were elevated in 7
(21%) iSLE patients and 10 (24%) SLE patients (Fig. 3).
Correlations in iSLE patients
In iSLE patients, IFN scores were correlated with pro-
portions of transitional B-cells, switched memory B-
cells, non-switched memory B-cells and plasma blasts/
plasma cells (Table 2). Also, IFN scores were positively
correlated with total IgG, anti-SSA and anti-Smith anti-
bodies, and negatively correlated with C3 and C4 in
iSLE patients. In addition, proportions of plasma blasts/
plasma cells and ABCs were positively correlated with
total IgG, while proportions of naı̈ve B-cells were nega-
tively correlated with total IgG. Proportions of switched
memory B-cells were correlated with anti-Smith antibod-
ies and with anti-SSA antibodies, while non-switched
memory B-cells were negatively correlated with anti-
SSA and anti-Smith antibodies. There was a negative
correlation between BAFF levels and proportions of total
memory B-cells and anti-dsDNA antibodies. BAFF levels
were not significantly correlated with IFN scores.
Correlations in SLE patients
Apart from transitional B-cells, none of the B-cell sub-
sets was correlated with IgG levels in SLE patients
(Table 2). There was a negative correlation between pro-
portions of plasma blasts/plasma cells and C4 levels.
IFN scores were positively correlated with proportions of
transitional B-cells, but negatively correlated with pro-
portions of total memory B-cells and C3. In addition,
IFN was correlated with anti-SSA and anti-Smith anti-
bodies. In SLE patients, BAFF levels were correlated
with IFN score. There was no correlation between BAFF
levels and proportions of B-cell subsets.
Discussion
The aim of this cross-sectional study was to investigate
whether there are distortions in B-cell subsets, IFN
scores and BAFF levels in iSLE patients, in order to bet-
ter understand the pathogenesis and maybe—in the fu-
ture—predict progression. Our findings highlight that
elevated levels of ABCs, switched memory B-cells and
increased IFN scores might play a crucial role in the
pathogenesis of SLE. We found that iSLE patients have
increased proportions of ABCs compared with HCs. In
addition, IFN scores and BAFF levels were similarly ele-
vated in iSLE and SLE patients compared with HCs. In
iSLE patients, IFN score was correlated with proportions
of transitional B-cells, switched memory B-cells, plasma
blasts/plasma cells and established serological markers
for SLE including total IgG, anti-SSA and anti-Smith
TABLE 1 Demographics, disease characteristics and medication use
Characteristics HC (n 5 22) iSLE (n 5 34) SLE (n 5 41)
Age, years 45 (28–58) 45 (29–63) 43 (30–51)
Female sex, n (%) 18 (82) 27 (79) 34 (83)
Ethnicity, n (%)
Caucasian 22 (100) 30 (88) 37 (90)
Asian NA 2 (6) 1 (2)
Other NA 2 (6) 3 (7)
Time since first complaints, months NA 14 (5–36) 32 (18–52)
Number of SLICC criteria NA 3 (2–3) 5 (5–6)
Number of ACR criteria NA 3 (2–3) 5 (4–6)
SLEDAI score NA 0 (0–2) 2 (0–4)
Increased total IgG (>16 g/l) 1 (5) 7 (21) (n ¼ 33)a 3 (7)
Positive anti-dsDNA (>15 IU/ml) 0 8 (24) (n ¼ 33)a 17 (42)
Positive anti-SSA (>10 U/ml) 0 16 (47) 12 (29)
Positive anti-Smith (>10 U/ml) 0 1 (3) 5 (12)
C3 decreased (<0.9 g/l) NA 5 (15) 12 (29)
C4 decreased (<0.1 g/l) NA 2 (6) 7 (17)
Medication use
NSAIDs NA 9 (28) 8 (20)
Prednisone NA 0 12 (29)
HCQ NA 10 (29) 34 (83)
AZA NA 0 6 (15)
MMF NA 0 8 (20)
aData are reported as median (interquartile range) or n (%). Baseline data not available for all participants. HCs: healthy
controls; iSLE: incomplete SLE; NA: not applicable.
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FIG. 1 Proportions of B-cell subsets in HCs, iSLE patients and SLE patients
Medians and IQR are depicted for every group. Proportions of transitional B-cells (A), naı̈ve B-cells (B), plasma
blasts/plasma cells (C), memory B-cells (D) and IgD-only memory B-cells (G) were not different between all groups.
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antibodies, and complement levels. This finding sug-
gests that a more activated B-cell compartment, in
terms of increased proportions of plasma cells, ABCs
and switched memory B-cells, is reflected by higher
(auto)antibody production. Also, we found that iSLE
patients with high IFN scores had higher proportions of
switched memory B-cells and transitional B-cells and
serological disease markers than iSLE patients with low
IFN scores.
It has been demonstrated that IFN type I-induced
gene transcripts are increased in blood and tissue of the
majority of SLE patients, as a consequence of a persist-
ent self-directed immune reaction, and are found to be
of importance in the early phase of SLE [21, 22]. Chiche
et al. [11] showed that IFN-induced genes can be clus-
tered in three different modules, including a stable mod-
ule (M1.2), driven by IFN-a, and variable modules (M3.4
and M5.12), also induced by IFN-b and -c. In order to
improve comparability with previous studies, we calcu-
lated an IFN score based on three IFN genes (IFI44L,
LY6E and MX1) from M1.2, that are among the most fre-
quently tested in SLE patients [11, 23]. We found that
this IFN score was elevated in iSLE and in SLE patients
compared with HCs. Interestingly, a clear dichotomy
was observed in the distribution of IFN scores within the
iSLE group, since approximately half had elevated IFN
scores. Although there is considerable heterogeneity
among iSLE patients, others have found similar distribu-
tions of IFN scores in iSLE patients [24]. It is unclear
why this division occurs. Possibly, iSLE patients with
high IFN scores have higher risk of progressing to SLE.
However, this needs to be confirmed in future longitu-
dinal studies.
It has been reported that IFN-a activity increases
gradually before diagnosis of SLE and that higher IFN-a
activity is linked with an increase in autoantibodies [25].
Additionally, Li et al. [24] showed that IFN-induced gene
expression was correlated with SLE autoantibody pro-
files, measured with an autoantibody proteomic array, in
iSLE patients. In line with the study by Li et al. [24] we
demonstrated a positive correlation between IFN score
and anti-SSA and anti-Smith antibodies. In the present
study, IFN scores were similar in iSLE patients and SLE
patients. This might be explained by the fact that all the
included SLE patients had quiescent disease and
received immunosuppressive therapy [26].
IFN can also stimulate BAFF production, which stimu-
lates B-cell maturation and, when dysregulated, can
prevent apoptosis of autoreactive B-cells leading to
autoimmunity [25]. In our study, BAFF levels were also
elevated in iSLE (and SLE) patients compared with HCs,
which supports its role in the pathogenesis of SLE.
Others have also found increased BAFF levels in iSLE
FIG. 1 Continued
Switched memory B-cells were elevated in SLE patients compared with HCs (E). Non-switched memory B-cells were
decreased in SLE patients compared with HCs and iSLE patients (F). ABCs were elevated in iSLE and SLE patients
compared with HCs (H). *P<0.05, **P< 0.01. HCs: healthy controls; iSLE: incomplete SLE; IQR: interquartile range;
ABCs: age-associated B-cells.
FIG. 2 IFN scores in HCs, iSLE patients and SLE
patients
Medians and IQR are depicted for every group. The
dotted line represents the median IFN score of the iSLE
group. IFN scores were increased in iSLE and SLE
patients compared with HCs. *P< 0.05, **P<0.01. HCs:
healthy controls; iSLE: incomplete SLE; IQR: interquartile
range.
FIG. 3 Levels of BAFF in HCs, iSLE patients and SLE
patients
Medians and IQR are depicted for every group. The
dotted line represents þ2 S.D. above the mean of the
HC group, which was used as cut-off for BAFF positiv-
ity. BAFF levels were higher in the iSLE and SLE groups
compared with HCs. *P< 0.05, **P< 0.01. BAFF: B-cell-
activating factor; HCs: healthy controls; iSLE: incom-
plete SLE; IQR: interquartile range.
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patients [27]. In a study by Munroe et al. [28] BAFF lev-
els were measured in relatives of SLE patients.
Interestingly, relatives who later developed SLE showed
elevated BAFF levels at baseline compared with un-
affected relatives. However, BAFF did not independently
predict transitioning to classified SLE in the study by
Munroe et al. Nonetheless, it has been described that
belimumab, which targets BAFF, has therapeutic benefit
in active SLE patients [13]. As class-switched memory
B-cells and plasma blasts were substantially depleted
under belimumab, belimumab could be of interest for
iSLE patients [13].
We found that IFNhigh iSLE patients had higher pro-
portions of switched memory B-cells and transitional B-
cells and serological disease markers than IFNlow iSLE
patients. Concordantly, IFN scores were correlated with
proportions of switched memory B-cells and transitional
B-cells in iSLE patients. It has been demonstrated that
elevated proportions of transitional B-cells are present in
SLE patients and reflect an early checkpoint in the gen-
eration of autoreactive B-cells [29, 30]. In a recent study,
RNA sequencing of sorted transitional B-cells from un-
treated SLE patients revealed a predominant overex-
pression of IFN-stimulated genes [30].
In addition, switched memory cells tended to be ele-
vated in iSLE patients compared with HCs. Upon activa-
tion, these cells can rapidly differentiate into plasma
cells and therefore play a crucial role in the pathogen-
esis of SLE [31]. Conversely, proportions of non-
switched memory B-cells were decreased in iSLE
patients. Non-switched memory B-cells can re-enter
germinal centre reaction after antigenic stimulation [31].
In line with this observation, elevated proportions of
switched memory B-cells and decreased levels of non-
switched memory B-cells in SLE patients have been
observed previously [15]. In the current study, switched
memory B-cells correlated with anti-SSA and anti-Smith
antibodies, which underlines that this B-cell subset is
associated with autoantibody production. Arbuckle et al.
[32] investigated development of autoantibodies before
the clinical onset of SLE, and showed that at least one
SLE-specific autoantibody was present years before
diagnosis (mean 3.3 years). They also showed that more
individuals had anti-SSA autoantibodies before they be-
came positive for anti-dsDNA. Indeed, in our iSLE
patients, almost half of patients were anti-SSA positive
and proportions of B-cell subsets were correlated with
IgG levels or specific autoantibodies. Consequently, for
studying progression from iSLE to SLE it is important to
measure both specific B-cell subsets and specific auto-
antibodies. Also, proportions of switched memory B-
cells and plasma cells were correlated with IFN scores,
which supports the notion that IFN may be involved in
isotype switching [12].
Lastly, we analysed proportions of ABCs
(CD19þCD21lowCD11cþ). As described by Rubtsova
et al. [17] ABCs are a functionally unique B-cell subset
that accumulate with age, and probably arise from acti-
vation driven differentiation, leading to upregulation of
the transcription factor T-bet. Although measurement of
T-bet was not included in our study, CD21lowCD11cþ
cells can be regarded as ABCs. In a recent review,
Naradikian et al. [18] proposed that ABCs are a memory
subset generated by nucleic acid-containing antigens in
the context of a proinflammatory cytokine milieu.
Normally, B-cells that internalize nucleic acid containing
self-antigens fail to survive because they lack the cog-
nate T-cell interactions and appropriate cytokine signals
to further differentiate and survive. However, inadvertent
or aberrant receipt of these signals can afford survival of
TABLE 2 Correlations between B-cell subsets, interferon scores, BAFF levels, autoantibodies and complement factors in
iSLE and SLE patients







iSLE SLE iSLE SLE iSLE SLE iSLE SLE iSLE SLE iSLE SLE iSLE SLE iSLE SLE
Trans 0.50** 0.49** 0.47**
Naı̈ve 0.36*
Memory 0.38* 0.35* 0.39*
SMB 0.47** 0.40*
NSMB 0.51** 0.44* 0.40*
PB/PC 0.38* 0.48**
ABC 0.39*
IFN NA NA 0.35* 0.44* 0.51* 0.39* 0.41* 0.42* 0.46** 0.32* 0.48**
BAFF 0.35* NA NA 0.42*
Correlation coefficients were calculated with Spearman correlation. *P<0.05, **P<0.01. BAFF: B-cell-activating factor;
iSLE: incomplete SLE; Trans: proportions of transitional B-cells; Naı̈ve: proportions of naı̈ve B-cells; Memory: proportions
of memory B-cells; SMB: proportions of switched memory B-cells; NSMB: proportions of non-switched memory B-cells;
PB/PC: proportions of plasma blasts/plasma cells; ABCs: proportions of age-associated B-cells; C3 and C4: complements
3 and 4; NA: not applicable.
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these cells and enable their recruitment into a long-lived
memory and effector ABC pool, which can produce
autoantibodies [18]. We observed elevated proportions
of ABCs in iSLE patients and SLE patients compared
with HCs [18]. Even more, a significant correlation be-
tween ABCs and IgG levels was found in iSLE patients,
which supports their antibody-producing function in
autoimmunity.
Limitations
There are some limitations to this study that need men-
tioning. Our data only reflect values of SLE patients with
quiescent disease who were being treated at the time of
inclusion. Thus, our results cannot be translated to SLE
patients with active disease (SLEDAI >4). Also, SLE
patients used more immunosuppressive medication than
iSLE patients. This could have influenced B-cell subsets,
IFN scores, BAFF levels, complement levels and anti-
body titres. In addition, our study design is cross-
sectional and comprises a relatively small sample size.
Thus, it should be noted that correlations with P<0.05
should be regarded as borderline significance and re-
quire confirmation in future studies.
Conclusion
In summary, iSLE patients showed increased propor-
tions of ABCs compared with HCs. IFN scores were
increased and correlated with proportions of transitional
B-cells, switched memory B-cells, plasma cells and
anti-SSA and anti-Smith antibodies. Moreover, we found
that iSLE patients with high IFN scores had higher pro-
portions of transitional B-cells, plasma cells and
switched memory B-cells and higher serological disease
markers than iSLE patients with low IFN scores. Our
findings suggest that IFN and distortions of B-cell sub-
sets are involved in the early steps of the pathogenesis
of SLE. Possibly, these iSLE patients are more at risk to
progress to SLE. However, this should be confirmed
with longitudinal data.
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Disclosure statement: The authors have declared no
conflicts of interest.
Supplementary data
Supplementary data are available at Rheumatology online.
References
1 Tsokos GC, Lo MS, Reis PC, Sullivan KE. New
insights into the immunopathogenesis of systemic lupus
erythematosus. Nat Rev Rheumatol 2016;12:716–30.
2 Cohen AS, Tan EM, Mcshane DJ et al. The 1982
revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum 1982;25:1271–7.
3 Petri M, Orbai AM, Alarcón GS et al. Derivation and
validation of the systemic lupus international
collaborating clinics classification criteria for systemic
lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
4 Aringer M, Costenbader K, Daikh D et al. 2019
European League Against Rheumatism/American College
of Rheumatology Classification Criteria for Systemic
Lupus Erythematosus. Arthritis Rheumatol 2019;71:
1400–12.
5 Swaak AJ, van de Brink H, Smeenk RJ et al.
Incomplete lupus erythematosus: results of a multicentre
study under the supervision of the EULAR Standing
Committee on International Clinical Studies Including
Therapeutic Trials (ESCISIT). Rheumatology (Oxford)
2001;40:89–94.
6 Lambers WM, Westra J, Jonkman MF, Bootsma H,
de Leeuw K. Incomplete systemic lupus erythematosus
– what remains after application of ACR and SLICC
criteria? Arthritis Care Res (Hoboken) 2019; doi:
10.1002/acr.23894 [Epub ahead of print].
7 Pascual V, Chaussabel D, Banchereau J. A genomic
approach to human autoimmune diseases. Annu Rev
Immunol 2010;28:535–71.
8 Banchereau J, Pascual V. Type I interferon in systemic
lupus erythematosus and other autoimmune diseases.
Immunity 2006;25:383–92.
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